全部 |
  • 全部
  • 题名
  • 关键词
  • NSTL主题词
  • 摘要
  • 论文-出处
  • 论文-作者
  • 论文-机构
  • 论文-DOI
  • 期刊-出版者
  • 期刊-出版地
  • 期刊-主编
  • ISSN
  • EISSN
  • ISBN
  • EISBN
检索 搜索期刊 二次检索 AI检索
外文文献 中文文献
筛选条件:

1. Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework NSTL国家科技图书文献中心

Shemesh, Colby S. |  Chan, Phyllis... -  《Clinical Pharmacology and Therapeutics》 - 2023,114(3) - 644~651 - 共8页

摘要:We assess the longitudinal tumor growth inhibition (TGI) metrics and overall survival (OS) predictions applied to patients with advanced biliary tract cancer (BTC) enrolled in IMbrave151 a multicenter...
关键词: SIZE RESPONSE METRICS |  PREDICT SURVIVAL |  SIMULATIONS |  BEVACIZUMAB |  ONCOLOGY

2. Pharmacokinetics and Exposure-Response Analysis of Venetoclax plus Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial SCIE Web of Science核心 NSTL国家科技图书文献中心

Samineni, Divya |  Gibiansky, Leonid... -  《Advances in therapy.》 - 2022,39(8) - 3635~3653 - 共19页

摘要:Introduction This study aims to investigate pharmacokinetics (PK) and exposure-response parameters of the 400 mg once-daily venetoclax dose regimen in combination with obinutuzumab, which was approved...
关键词: Drug safety |  Effectiveness |  Cancer |  Pharmacokinetics |  BCL-2 INHIBITOR |  17P DELETION |  OPEN-LABEL |  CHLORAMBUCIL |  MULTICENTER |  RITUXIMAB...

3. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer SCOPUS Scopus数据库 SCIE Web of Science核心 NSTL国家科技图书文献中心

Lu, Dan |  Li, Chunze... -  《Cancer chemotherapy and pharmacology.》 - 2019,84(1) - 175~185 - 共11页

摘要:PurposeThe phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor...
关键词: Trastuzumab emtansine (T-DM1) |  HER2 |  Pharmacokinetics |  Previously untreated metastatic breast cancer |  MARIANNE

4. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma SCIE Web of Science核心 NSTL国家科技图书文献中心

Zhu, Rui |  Zheng, Yanan... -  《Pulmonary pharmacology & therapeutics》 - 2017,46 - 88~98 - 共11页

摘要:Lebrikizumab is a humanized monoclonal antibody that binds to interleukin-13 and has been evaluated as a treatment for moderate-to-severe asthma. Objectives of this work were to characterize lebrikizu...
关键词: Asthma |  Anti-IL-13 |  Lebrikizumab |  Population PK |  Exposure-response |  Monoclonal antibody

6. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework

Chan, Phyllis |  Marchand, Mathilde... -  《CPT: Pharmacometrics & Systems Pharmacology》 - 2021,10(10) - 1171~1182 - 共12页

摘要:The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and assess the impact ...
关键词: OPEN-LABEL |  CANCER |  MULTICENTER |  ONCOLOGY |  SIZE |  THERAPEUTICS |  ASSOCIATION |  SIMULATION |  DOCETAXEL |  KINETICS

7. Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Svensson, Robin J. |  Ribbing, Jakob... -  《CPT: Pharmacometrics & Systems Pharmacology》 - 2021,10(10) - 1221~1235 - 共15页

摘要:Identification of covariates, including biomarkers, spirometry, and diaries/questionnaires, that predict asthma exacerbations would allow better clinical predictions, shorter phase II trials and infor...
关键词: UNCONTROLLED ASTHMA |  END-POINTS |  MODEL |  DISEASE |  TRIALS |  COUNT |  PSN
检索条件作者:Vadhavkar, Shweta

NSTL主题词

  • NSTL学科导航